Last reviewed · How we verify
Minipress (PRAZOSIN)
Prazosin (Minipress), marketed by Pfizer, is an established hypertension treatment with a key composition patent expiring in 2028. Its mechanism of action, targeting the alpha-1A adrenergic receptor, provides a distinct therapeutic profile for relaxing blood vessels and reducing blood pressure. The primary risk is competition from off-patent drugs like doxazosin, which has 18 generics available since its FDA approval in 1990.
At a glance
| Generic name | PRAZOSIN |
|---|---|
| Sponsor | Pfizer |
| Drug class | alpha-Adrenergic Blocker |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 1976 |
Approved indications
- Hypertension
Common side effects
- dizziness
- headache
- drowsiness
- lack of energy
- weakness
- palpitations
- nausea
Drug interactions
- cardiac glycosides (digitalis, digoxin)
- hypoglycemics (insulin, chlorpropamide, phenformin, tolazamide, tolbutamide)
- tranquilizers and sedatives (chlordiazepoxide, diazepam, phenobarbital)
- antigout (allopurinol, colchicine, probenecid)
- antiarrhythmics (procainamide, propranolol, quinidine)
- analgesics, antipyretics, and anti-inflammatories (propoxyphene, aspirin, indomethacin, phenylbutazone)
- diuretics or other antihypertensive agents
- phosphodiesterase-5 (PDE-5) inhibitors
Key clinical trials
- Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin (PHASE1,PHASE2)
- Alpha-1 Blockade for Alcohol Use Disorder (AUD) (PHASE2)
- A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults (PHASE1)
- Brain Blood Vessel Responses to Changes in Blood Flow (PHASE2)
- Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests (PHASE3)
- Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort (PHASE2)
- Prazosin for Alcohol Use Disorder With Withdrawal Symptoms (PHASE2)
- Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minipress CI brief — competitive landscape report
- Minipress updates RSS · CI watch RSS
- Pfizer portfolio CI